Skip to main content

ORIGINAL RESEARCH article

Front. Genet.
Sec. Cancer Genetics and Oncogenomics
Volume 15 - 2024 | doi: 10.3389/fgene.2024.1405825

High expression of TBC1 domain family member 22A is related to poor prognosis in ovarian serous cystadenocarcinoma

Provisionally accepted
Xiaofeng Lv Xiaofeng Lv 1Ruyue Gong Ruyue Gong 2Lili Guo Lili Guo 3Changyu Wang Changyu Wang 3*
  • 1 Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
  • 2 Third Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan Province, China
  • 3 Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technolo, Wuhan, China

The final, formatted version of the article will be published soon.

    Objective: TBC1 domain family member 22A (TBC1D22A) possesses GTPase-activating protein (GAP) activity of Rab family proteins and has not been reported in ovarian serous cystadenocarcinoma (OSC). The research was designed to evaluate the expression and prognostic effect of TBC1D22A in OSC. Methods: TCGA, GTEx, GEO, HPA, and GDSC databases were adopted to explore the oncogenic mechanism of TBC1D22A in OSC, as well as the correlation between TBC1D22A and patient prognosis, IC50, stemness index, immune checkpoint, and immune infiltration. To compare the occurrence of end-point times, Kaplan-Meier survival curves were used. Independent prognostic factors of patients with OSC were analyzed with both univariate as well as multivariate Cox regression analyses, and the overall survival (OS) of the patients at 1, 2 and 3 years was predicted with nomograms. Results: TB1D22A expression was elevated in OSC, and high expression of TBC1D22A was related to poor OS, progression free survival (PFS), disease specific survival (DSS), and disease-free survival (DFS) in OSC. TBC1D22A had predictive value in both univariate and multivariate Cox regression analysis. TBC1D22A was positively correlated with M2 macrophage infiltration and the expression of most immune checkpoint genes. IC50 for cisplatin and paclitaxel increased in patients with overexpression of TBC1D22A. Conclusion: TBC1D22A is an independent prognostic risk factor for patients of ovarian cancer. Future research is required to fully understand the carcinogenic mechanism and clinical utility of TBC1D22A in ovarian cancer.

    Keywords: TBC1D22A, prognosis, TCGA, Ovarian serous cystadenocarcinoma, Immune Cell Infiltration

    Received: 23 Mar 2024; Accepted: 09 Sep 2024.

    Copyright: © 2024 Lv, Gong, Guo and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Changyu Wang, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technolo, Wuhan, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.